Introduction & Objective: To assess the treatment effects of once-weekly (OW) insulin icodec (icodec) vs once-daily (OD) basal insulin comparators ± concomitant glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in ONWARDS 1-5.

Methods: A post hoc analysis by trial of insulin-naïve (ONWARDS 1, 3, 5) and insulin-experienced (ONWARDS 2, 4) adults with type 2 diabetes (T2D).

Results: Participants on icodec vs OD comparators had larger or similar A1C reductions from baseline (BL) to end of treatment (EOT) irrespective of GLP-1 RA use; there was no statistically significant treatment by subgroup interaction in A1C changes (Table). Overall rates of clinically significant or severe hypoglycemia were low (<1 event/patient-year of exposure) across arms among ONWARDS 1-3 and 5 subgroups, with numerically lower rates among GLP-1 RA users vs non-users; in ONWARDS 4 (basal-bolus trial), the hypoglycemia rate was similar among GLP-1 RA users vs non-users in the icodec arm (Table). There was no statistically significant treatment by subgroup interaction in any trial for the attainment of A1C <7% without clinically significant or severe hypoglycemia, nor body weight change from BL to EOT.

Conclusion: The efficacy and safety of icodec vs OD comparators was generally consistent among adults with T2D, irrespective of baseline GLP-1 RA use.

graphic
View largeDownload slide
Disclosure

T. Vilsbøll: Consultant; AstraZeneca. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Mundipharma. Advisory Panel; Novo Nordisk, Lilly Diabetes, Sanofi. Speaker's Bureau; Bayer Inc., Gilead Sciences, Inc. Advisory Panel; Sun Pharmaceutical Industries Ltd. Research Support; Lilly Diabetes. K.O. Bangsgaard: Employee; Novo Nordisk A/S. A. Fu: Employee; Novo Nordisk A/S, Novo Nordisk. M. Kellerer: Advisory Panel; Abbott. Speaker's Bureau; Daiichi Sankyo. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim. Advisory Panel; Sanofi, GlaxoSmithKline plc, AstraZeneca, Lilly Diabetes. Speaker's Bureau; Lilly Diabetes. Advisory Panel; Novo Nordisk. S.B. Søgaard: Employee; Novo Nordisk A/S. R. Goldenberg: Speaker's Bureau; Bayer Inc., Boehringer-Ingelheim. Advisory Panel; Eli Lilly and Company, HLS Therapeutics Inc., Novo Nordisk, Sanofi.

Funding

Novo Nordisk A/S

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.